By 2050, an estimated 13 million Americans will have Alzheimer’s disease.1 But despite its prevalence, there’s no known cure and its causes are hotly debated. While it’s often said that an accumulation of amyloid beta plaques underlies Alzheimer’s, there appears to be more to the story. It’s been suggested the plaques may be a symptom… Read More »
KHN chief Washington correspondent Julie Rovner discussed the FDA’s approval of a new drug for Alzheimer’s disease on WAMU’s “1A” on Wednesday. KHN correspondent Aneri Pattani discussed the increase in alcohol use and misuse by young women on NPR’s “All Things Considered” on Wednesday. KHN freelancer Harris Meyer discussed the FDA’s approval of a new… Read More »
WASHINGTON — Government health officials on Monday approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease. The Food and Drug Administration said it granted approval to the drug from Biogen based on results that… Read More »